Immune-Onc wins R&D Achievement of the Year for its first-in-class myeloid checkpoint inhibitors for cancer patients, including two programs in the clinic, and two deals with Regeneron Pharmaceuticals Inc. and BeiGene Ltd.
Need help?
Contact usImmune-Onc wins R&D Achievement of the Year for its first-in-class myeloid checkpoint inhibitors for cancer patients, including two programs in the clinic, and two deals with Regeneron Pharmaceuticals Inc. and BeiGene Ltd.